Risks and side effects of islet transplantation

被引：78

作者：

Ryan E.A. ^{[1
]}

Paty B.W. ^{[1
]}

Senior P.A. ^{[1
]}

Shapiro A.M.J. ^{[1
]}

机构：

[1] Clinical Islet Transplant Program, Edmonton, Alta. T6G 2C8

来源：

Current Diabetes Reports | 2004年 / 4卷 / 4期

关键词：

Tacrolimus; Hypoglycemia; Sirolimus; Portal Vein Thrombosis; Islet Transplantation;

D O I：

10.1007/s11892-004-0083-8

中图分类号：

学科分类号：

摘要：

Islet transplantation can deliver stable glycemic control, relief from recurrent severe hypoglycemia, and insulin independence. Accessing the portal vein via the percutaneous hepatic approach carries the risk of bleeding, and the infusion of islets a risk of portal vein thrombosis. In the long term, common minor problems with immunosuppression are mouth ulcers, diarrhea, and acne. Longer-term risks include malignancy and serious infection, both rare to date in clinical islet transplantation. Sensitization to donor antigens may also occur. The long-term diabetes complications may stabilize, but of this aspect little is known to date. In the short term, there may be some elevation of serum cholesterol and blood pressure, in some patients there has been a decline in renal function, and in a few, acute retinal bleeds. For most, improvement in glucose control with resolution of glycemic lability and hypoglycemia, has been a net benefit Copyright © 2004 by Current Science Inc.

引用

页码：304 / 309

页数：5

共 55 条

[41]

Jim B., Doyle A., Bloom R.D., Rapamycin is associated with worsening proteinuria in transplant patients with renal injury: A report of four cases, J. Am. Soc. Nephrol., 14, (2003)

[42]

Fioretto F., Steffes M.W., Sutherland D.E., Et al., Reversal of lesions of diabetic nephropathy after pancreas transplantation, N. Engl. J. Med., 339, pp. 69-75, (1998)

[43]

Groth C.G., Backman L., Morales J.M., Et al., Sirolimus (rapamycin)-based therapy in human renal transplantation, Transplantation, 67, pp. 1036-1042, (2002)

[44]

Trotter J.F., Wachs M.E., Trouillot T.E., Et al., Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not with tacrolimus, Liver Transpl., 7, pp. 401-408, (2001)

[45]

Fiorina P., La Rocca E., Venturini M., Et al., Effects of kidney- pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes, Diabetes, 50, pp. 496-501, (2001)

[46]

Navarro X., Sutherland D.E., Kennedy W.R., Long-term effects of pancreatic transplantation on diabetic neuropathy, Ann. Neurol., 42, pp. 727-736, (1997)

[47]

Brendel M.D., Hering B., Schulz A.O., Bretzel R.G., International Islet Transplant Registry Report, (1999)

[48]

Luzi L., Perseghin G., Brendel M.D., Et al., Metabolic effects of restoring partial beta-cell function after islet allo- transplantation in type 1 diabetic patients, Diabetes, 50, pp. 277-282, (2001)

[49]

Jaeger C., Brendel M.D., Hering B.J., Et al., Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts, Diabetes, 46, pp. 1907-1910, (1997)

[50]

Bosi E., Braghi S., Maffi P., Et al., Autoantibody response to islet transplantation in type 1 diabetes, Diabetes, 50, pp. 2464-2471, (2001)

← 1 2 3 4 5 6 →